{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:04:05Z","timestamp":1790309045075,"version":"4.1.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.01067","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T05:22:01Z","timestamp":1571116921000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":56,"title":["Randomized Phase II Trial of Triapine-Cisplatin-Radiotherapy for Locally Advanced Stage Uterine Cervix or Vaginal Cancers"],"prefix":"10.3389","volume":"9","author":[{"given":"Charles A.","family":"Kunos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Sook","family":"Chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Percy","family":"Ivy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"B1","unstructured":"New York, NYWorld Health OrganizationGLOBOCAN 2018 Cancer Incidence and Mortality Worldwide2019"},{"key":"B2","volume-title":"Cancer Facts & Figures 2019","year":"2019"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1097\/IGC.0b013e31821dc8b5","article-title":"18F-fluoro-2-deoxy-D-glucose positron emission tomography standard uptake value ratio as an indicator of cervical cancer chemoradiation therapeutic response","volume":"21","author":"Kunos","year":"2011","journal-title":"Int J Gynecol Cancer."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1097\/IGC.0b013e318270577f","article-title":"Elevated ribonucleotide reductase levels associate with suppressed radiochemotherapy response in human cervical cancers","volume":"22","author":"Kunos","year":"2012","journal-title":"Int J Gynecol Cancer."},{"key":"B5","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/IGC.0b013e31828b4eb5","article-title":"Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis","volume":"23","author":"Kunos","year":"2013","journal-title":"Int J Gynecol Cancer."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1158\/1078-0432.Ccr-09-2469","article-title":"Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer","volume":"16","author":"Kunos","year":"2010","journal-title":"Clin Cancer Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ygyno.2013.04.019","article-title":"Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers","volume":"130","author":"Kunos","year":"2013","journal-title":"Gynecol Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1200\/jco.2002.20.4.966","article-title":"Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix","volume":"20","author":"Pearcey","year":"2002","journal-title":"J Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1056\/nejm199904153401502","article-title":"Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer","volume":"340","author":"Rose","year":"1999","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1200\/jco.2006.09.4532","article-title":"Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Rose","year":"2007","journal-title":"J Clin Oncol."},{"key":"B11","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/0360-3016(93)90462-5","article-title":"Weekly cisplatin plus external beam radiotherapy and high dose rate brachytherapy in patients with locally advanced carcinoma of the cervix","volume":"27","author":"Souhami","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1056\/nejm199904153401503","article-title":"Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma","volume":"340","author":"Keys","year":"1999","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2161-0932.S4-001","article-title":"Molecular strategies of deoxynucleotide triphosphate supply inhibition used in the treatment of gynecologic malignancies","volume":"4","author":"Kunos","year":"2011","journal-title":"Gynecol Obstet (Sunnyvale)"},{"key":"B14","first-page":"55","article-title":"Therapeutic mechanisms of treatment in cervical and vaginal cancer","volume":"8","author":"Kunos","year":"2012","journal-title":"Oncol Hematol Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"7834","DOI":"10.1074\/jbc.M512894200","article-title":"Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells","volume":"281","author":"Hakansson","year":"2006","journal-title":"J Biol Chem"},{"key":"B16","doi-asserted-by":"publisher","first-page":"33021","DOI":"10.1074\/jbc.M005337200","article-title":"Cross-talk between the allosteric effector-binding sites in mouse ribonucleotide reductase","volume":"275","author":"Reichard","year":"2000","journal-title":"J Biol Chem"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1158\/1078-0432.Ccr-05-2860","article-title":"In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone)","volume":"12","author":"Barker","year":"2006","journal-title":"Clin Cancer Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1667\/rr1858.1","article-title":"Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein","volume":"172","author":"Kunos","year":"2009","journal-title":"Radiat Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1667\/rr2273.1","article-title":"Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers","volume":"174","author":"Kunos","year":"2010","journal-title":"Radiat Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1667\/RR2556.1","article-title":"Deoxynucleoside salvage facilitates DNA repair during ribonucleotide reductase blockade in human cervical cancers","volume":"176","author":"Kunos","year":"2011","journal-title":"Radiat Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00280-002-0480-0","article-title":"Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule","volume":"50","author":"Feun","year":"2002","journal-title":"Cancer Chemother Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1200\/jco.2004.07.158","article-title":"Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone administered by 96-hour intravenous continuous infusion","volume":"22","author":"Wadler","year":"2004","journal-title":"J Clin Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00280-016-3200-x","article-title":"Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies","volume":"79","author":"Kunos","year":"2017","journal-title":"Cancer Chemother Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1200\/jco.1999.17.5.1339","article-title":"Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study","volume":"17","author":"Whitney","year":"1999","journal-title":"J Clin Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1006\/gyno.1997.4761","article-title":"Hydroxyurea, 5-fluorouracil infusion, and cisplatin adjunct to radiation therapy in cervical carcinoma: a phase I-II trial of the Gynecologic Oncology Group","volume":"66","author":"Stehman","year":"1997","journal-title":"Gynecol Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2217\/fon.11.147","article-title":"Management of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone-induced methemoglobinemia","volume":"8","author":"Kunos","year":"2012","journal-title":"Fut Oncol."},{"key":"B27","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations","volume":"35","author":"Young","year":"1999","journal-title":"Eur J Cancer."},{"key":"B28","first-page":"1059","article-title":"Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials","volume":"47","author":"Shankar","year":"2006","journal-title":"J Nucl Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst."},{"key":"B30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3389\/fonc.2018.00149","article-title":"Triapine radiochemotherapy in advanced stage cervical cancer","volume":"8","author":"Kunos","year":"2018","journal-title":"Front Oncol."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01067\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T05:22:05Z","timestamp":1571116925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01067\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":30,"alternative-id":["10.3389\/fonc.2019.01067"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.01067","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]},"article-number":"1067"}}